Actithera Secures $75.5M Series A to Advance FAP-Targeted Radioligand Therapies

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A round of $75.5 million. The financing was co-led by founding investor M Ventures alongside new leads Hadean Ventures, Sofinnova Partners and 4BIO Capital, with participation from Bioqube Ventures, Surveyor Capital and others.

Proceeds will underwrite the clinical development of Actithera’s lead fibroblast activation protein (FAP)-targeting radioligand candidate across multiple oncology indications and fuel expansion of its proprietary three-pillar discovery platform. This chemistry-driven platform combines covalent-targeting strategies, rational drug design and isotope-agnostic radiochemistry to maximize tumour residence time, ensure rapid systemic clearance and enhance safety and efficacy. Validation through the company’s FAP programme has yielded a best-in-class candidate distinguished by optimal pharmacokinetics and tumour specificity.

Founded and led by medicinal chemistry expert Dr Andreas Goutopoulos, whose 25-year track record includes over a dozen development candidates, Actithera now welcomes new Board members from Hadean Ventures, Sofinnova Partners, 4BIO Capital and Bioqube Ventures. These additions bolster the leadership team as Actithera advances its next-generation RLT pipeline.